GlowDx is a molecular diagnostics company that employs novel molecular science to provide emerging markets with high quality diagnostic tests; focusing on infectious disease. We diagnose of infectious disease through the consolidation of strategic technology assets & aggressive R&D programme.

In 2016 the Global Molecular Diagnostics Segment was valued at $10.6B. The segment is expected to grow (CAGR 14.3%) to reach $23.8B in 2022.